Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.

Assi MilwidskyShir FrydmanMichal Laufer-PerlBen SadehOrly SapirYoav GranotAviram HochstadtLiuba KorotetskiLiora KetchkerYan TopilskyShmuel BanaiOfer Havakuk

Published in: ESC heart failure (2022)

consumption, and BNP after switching from milrinone to levosimendan based IIT.

Keyphrases

cardiac surgery
acute kidney injury
ejection fraction
high intensity
stem cells
mesenchymal stem cells
bone marrow
smoking cessation
replacement therapy